A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
about
Interleukin 2 receptor antagonists for kidney transplant recipientsInterleukin 2 receptor antagonists for kidney transplant recipientsCurrent state of renal transplant immunosuppression: Present and futureInterleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials.The use of basiliximab in solid organ transplantation.Antibodies in the prevention of renal allograft rejection.Current and future immunosuppressive strategies in renal transplantation.Renal transplantation, immunosuppression and the skin: an update.Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.Blocking MHC class II on human endothelium mitigates acute rejectionThe role of basiliximab induction therapy in organ transplantation.Invasive mold infections: recent advances in management approaches.Antibody immunosuppressive therapy in solid-organ transplant: Part I.Current landscape for T-cell targeting in autoimmunity and transplantation.Neurological complications of transplantation.Basiliximab: efficacy and safety evaluation in kidney transplantation.Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and resultsEffects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children.Interleukin receptor antagonist induction in kidney transplantation: Is it worth the price?Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis.Multivariate analysis of antibody induction therapy and their associated outcomes in live donor kidney transplantation in the recent era.Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine.Efficacy of basiliximab induction in poorly matched living donor renal transplantation.Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.The role of basiliximab in the evolving renal transplantation immunosuppression protocol.Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience.Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation.Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation.Basiliximab in association with tacrolimus and steroids in caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization time.Long-term outcome of ATG vs. Basiliximab induction.
P2860
Q24240492-66AC3D94-E841-4FAD-B5EC-1F46E738057EQ24247441-D44ABC0A-12D3-46E1-B8D2-B05D83848E84Q26829789-EA7C9451-7A69-4DCB-8B11-059EFAFB6F98Q30725010-F59B2DAA-285F-481A-B81B-E728994D8382Q35000988-20947724-EF64-4E62-B4CF-124BA5796FDAQ35681527-9767D2BB-54ED-44D3-92CB-BBDEF2C2A74AQ35906315-8F5E5A1A-2A53-4CFE-AB9F-D10604AA13DCQ36000874-56D3883A-C7D8-44BA-86ED-04F11F6FC69CQ36505748-0B97479D-10DD-4D96-A4E0-B5EDB4F9B637Q36588477-13D37D80-A789-4273-8B29-11DC527A21E1Q36675465-E864C7E6-CC17-470B-B5B9-FC1C068100A8Q37428946-1C4AD23C-C31F-43A4-8B1F-BACD4B1ABE8DQ37691180-D7B06429-1912-4E7C-B6B6-F713EE87CA87Q37900647-0DE77F11-7A96-449D-9B4C-28A59871CF91Q37901973-F57B4256-4DED-406A-B767-00EB33F9A7A7Q38165224-9B028C7D-4E5C-4357-AC4F-9AD98754DD22Q38614123-E9656B06-A474-4E32-AD44-9E2F0A02B696Q40704973-12924687-3F92-444C-8CCB-458109AD6F79Q41475881-C09BC6DA-C02D-4556-8450-1D27A0563748Q41828996-2690D2E4-9DA6-4B99-9B62-943FD5A080E6Q42213452-5EF2A890-7973-466D-B34E-8117FE1FB4ACQ42618041-518841A5-3175-4314-BA93-F1665C1CD19FQ42679476-139C80C6-5F53-46E7-8FEA-6EF08AD04F90Q42693369-B41566C6-8F91-4622-9847-B1594EAC3CC9Q42866457-AA435439-5828-41F8-88BA-132E2B84CB8CQ43071206-68A680BF-84BF-4B24-8F94-9179AC1CD5AAQ43078141-8DD0E1BB-6219-45D6-8D41-7CBB8A035878Q43078169-86F09712-2187-4C0B-BEEB-D031E18A8AF7Q44517184-8B87E2A9-A42D-45BA-B919-AA2AD93FF5C7Q44794104-61629C78-597C-49FA-8FC3-E47C6A85ACBBQ44796561-84AC4789-00C7-48A8-BFDC-4EF4B1E5DA4CQ52897493-74338779-8506-4AA0-BB9A-416DC1123184
P2860
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
A randomized, double-blind tri ...... kidney transplant recipients.
@en
A randomized, double-blind tri ...... kidney transplant recipients.
@nl
type
label
A randomized, double-blind tri ...... kidney transplant recipients.
@en
A randomized, double-blind tri ...... kidney transplant recipients.
@nl
prefLabel
A randomized, double-blind tri ...... kidney transplant recipients.
@en
A randomized, double-blind tri ...... kidney transplant recipients.
@nl
P2093
P1433
P1476
A randomized, double-blind tri ...... kidney transplant recipients.
@en
P2093
C Legendre
C Ponticelli
H Prestele
J Garcia-Martinez
P304
P356
10.1097/00007890-200110150-00014
P577
2001-10-01T00:00:00Z